Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Spark Capital Advisors(India) Private Limited
$35.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Actavis plc announces agreement with Aurobindo Pharma Ltd to divest commercial operations in seven Western European countries


Friday, 17 Jan 2014 09:50pm EST 

Actavis plc:Says that it intends to enter into an agreement for Aurobindo Pharma Ltd to acquire Actavis' generics commercial operations in seven markets in Western Europe.Says the transaction is conditional on certain antitrust approvals and completion of employee consultation processes.Says until the transaction is completed, Actavis will continue to operate the commercial businesses in a business-as-usual mode, providing full support to manage the business, introduce new products and maximize its partnership with customers.Says Rothschild and Latham & Watkins acted as sole financial adviser and legal counsel to Actavis, respectively.Says Jefferies International Limited acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. 

Company Quote

1093.05
1.45 +0.13%
26 Dec 2014